Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
Moodys
Mallinckrodt
Johnson and Johnson

Last Updated: September 27, 2022

Patents Expiring in February 2035


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Zealand Pharma ZEGALOGUE dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-001 Mar 22, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No See Plans and Pricing See Plans and Pricing IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Global Blood Theraps OXBRYTA voxelotor TABLET, FOR SUSPENSION;ORAL 216157-001 Dec 17, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y
Global Blood Theraps OXBRYTA voxelotor TABLET, FOR SUSPENSION;ORAL 216157-001 Dec 17, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
AstraZeneca
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.